Berkeley Lights Debuts in France as MImAbs Acquires Beacon® Optofluidic System for Antibody Discovery


Receive instant alerts for news on your actions. Claim your 1-week free trial for Street Insider Premium here.


EMERYVILLE, California and MARSEILLE, France, December 02, 2021 (GLOBE NEWSWIRE) – Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and MimAbs SAS, an emerging CRO that discovers and develops antibodies for the therapy and immunotechnology research, today announced the acquisition of the Berkeley Lights Beacon® system through a TechAccess subscription to help continue its mission to assist customers in the generation and validation of novel therapeutic antibodies against cancer and inflammatory diseases.

This is the first Beacon platform to be used in France, which allows MImAbs to continue its commitment to provide their research institutes, public technology transfer offices, biotechnology and biopharmaceutical customers with a fully-fledged platform. integrated for the development of antibody-based therapeutics in cancer and inflammation. the fields. The Beacon platform will replace the MImAbs hybridoma system.

“We are excited to lead the way in antibody discovery with Berkeley Lights,” said Thierry Jean, CEO of MImAbs. “In our first tests of the Beacon system, the results were better than we even thought possible. With its capabilities to meet a range of goals that fail with traditional technologies, increase yields and diversity otherwise, and within deadlines that are weeks not months, the Beacon system is a clear competitive advantage. for us. Our skills in immunization and immunogen design, generation of screening tools such as high expression transfectants and downstream biology of monoclonal antibodies provide an ideal environment to take full advantage of the technology. proven abilities related to speed and depth of repertoire analysis:

  • Ability to screen 40,000 to 100,000 B cells versus only 1,500 to 3,000 with a hybridoma leading to 50 to 100 leads;
  • Timing reduced by almost 90%; from 60 days with hybridoma to 7 days with the Beacon system; and
  • Possibility of establishing a cell test with adherent cells in just 6 weeks after installation.

“We look forward to supporting MImAbs as they move from hybridoma technology to the most advanced antibody discovery platform on the market today,” said Eric Hobbs, Ph.D., director General of Berkeley Lights. “Investigators need faster, better discovery technologies to serve patients faster and more efficiently, and Berkeley Lights can help meet that need. “

About MImAbsMImAbs was created as an independent company in December 2020 through the acquisition of the assets of the MI-mAbs immunotherapy demonstrator, founded in 2011, an academic laboratory of Aix-Marseille University.

Located in the historic cradle of the Immunopôle de Marseille, the MImAbs building houses a fully integrated suite of platforms covering all stages leading to preclinical proof of concept. All R&D projects are managed in an industrial spirit by a multidisciplinary team of experts specifically dedicated to antibody engineering, biochemistry, bioproduction and immunopharmacology. MImAbs has also established and continues to forge strategic scientific and technological partnerships with both academia and industry, in particular with CIPHE (Transgenic mouse model engineering and immunomonitoring).About Berkeley LightsBerkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights platform captures in-depth phenotypic, functional and genotypic information for thousands of individual cells in parallel and can also deliver the living biology customers want in the form of the best cells. Our platform is a fully integrated end-to-end solution, comprising proprietary consumables including our OptoSelect ™ reagent kits and chips, advanced automation systems and application software. We have developed the Berkeley Lights platform to provide the most advanced environment for rapid functional characterization of large-scale single cells, the goal of which is to set an industry standard for our customers throughout their production chain. value of cellular products.

The Berkeley Lights Beacon® and Lightning ™ systems and the Culture Station ™ instrument are FOR RESEARCH ONLY. Not for use in diagnostic procedures.

Forward-looking statementsTo the extent that the statements contained in this press release are not descriptions of historical fact concerning Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. These forward-looking statements involve substantial known and unknown risks and uncertainties relating to future events, and actual results and product performance could differ materially from those expressed or implied by the forward-looking statements. Berkeley Lights assumes no obligation to update or revise any forward-looking statements. For a more detailed description of the risks and uncertainties relating to the growth and continued development of the Company, see the statements in the “Risk Factors” sections and elsewhere, in our filings with the State Securities and Exchange Commission. -United.

Media contacts PR@berkeleylights.com Investor contact IR@berkeleylights.com

Main logo

Source: Berkeley Lights, Inc

Comments are closed.